Abbott India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Part of BSE 250 LargeMidCap Index BSE Quality Index BSE 200 Nifty LargeMidcap 250 BSE Healthcare
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Announcement Under Regulation 30.
30 Apr - Director Finance Jyoti Saraph resigns effective May 1, 2025, earlier than previously announced.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
24 Apr - Abbott India confirms non-applicability as Large Corporate per SEBI, zero borrowings as of March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
18 Apr - Appointment of Ms. Maithilee Mistry as Chief Financial Officer.
-
Announcement under Regulation 30 (LODR)-Change in Management
16 Apr - Resignation of Associate Director - New Product Introduction.
-
Announcement under Regulation 30 (LODR)-Change in Management
16 Apr - Appointment of Ms. Anushree Kunhambu as Associate Director, New Product Introduction and Therapy Area Strategy.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Sep 2022TranscriptPPTREC
-
Jun 2021TranscriptPPT
Abbott Group
The company is a part of Abbott Laboratories, USA which has a presence in 160 countries with leading medical devices, diagnostics, nutrition products, and branded generic medicines. [1]